APT member Marte Kierulf Åm har published encouraging results, summarised as follows:
Animal trials show that the hormone glucagon gives a larger increase of glucose level when it is administered into the peritoneal cavity than when it is infused in subcutaneous tissue. This can improve the glucose control in diabetes, as part of an intraperitoneal artificial pancreas.
The study is published in Scientific Reports and was performed by PhD candidate Marte Kierulf Åm and other members of the Artificial Pancreas Trondheim research group (APT) at NTNU, as part of our Double Intraperitoneal Artificial Pancreas project.
Publisert: 22. Oct 2020 - kl. 13:52
Sist oppdatert: 22. Oct 2020 - kl. 13:53